Wednesday, October 8, 2014

Water

It's after midnight and it's raining really hard outside. I love it when it rains at night. I can't stand rain during the day - it depresses me ... but the sound of night rain is soothing.

I like driving at night in the rain. Most people don't because they have a hard time seeing. Me, I've got my music to keep me company as I drive. Depending on where I'm headed, I listen to certain songs. Nothing like listening to Stevie Ray Vaughn as I'm driving down a highway. I haven't driven since the day before my surgery - my doctor hasn't cleared me yet.

When I was 'young and dumb' I smoked a lot of weed. I would smoke while driving down to the shore. I popped a lot of pills too. When you're young you think you are invincible, nothing bad will ever happen to you. You take risks, and boy did I take some risks in my life!

Looking back on my life would I have done anything different? No. I would not have changed a thing. I have never regretted the things I have done; I have regretted the things I have not done yet. As far as how I lived the first 50 years of my life I enjoyed the ride. I hope the second half of my life is just as wild and carefree.

I bought Margaret Atwood's new book: Stone Mattress

I really like her style of writing.

My mom made me laugh the other day. I have little papers with quotes everywhere in my room and in the small room that I use as an office. She asked me, 'what are these little papers?' I told her when I'm reading if I come across something that I really like, I write it down.

I wrote the following on the back of an envelope:

"Water does not resist. Water flows. When you plunge your hand into it, all you feel is a caress. Water is not a solid wall, it will not stop you. But water always goes where it wants to go, and nothing in the end can stand against it. Water is patient. Dripping water wears away a stone. Remember that, my child. Remember you are half water. If you can't go through an obstacle, go around it. Water does. ~ Margaret Atwood

I translated it for my mom and she really liked it. Then I showed her Margaret Atwood's new book.

Water ... I like that.

If you can't go through an obstacle, go around it.

Inspiring words.

Speaking of water, I applied warm wet compresses under my arm. Dr. Frazier told me to ice the area when it is swollen and then after a half hour to apply moist heat. It has really made a difference.








Tuesday, October 7, 2014

DCIS (my breast cancer)

DCIS - Stage 1A - breast cancer. I have read hundreds of articles about my cancer. My greatest fear is having a recurrence. We're still waiting for my tumor's genetic profile from Oncotype.

Fear is an emotion I rarely felt in my life. I was always a risk taker, but cancer has made me less mellow. What cancer hasn't done is take away my appreciation for life and all its beauty. Everyday I wake up and thank my lucky stars for another beautiful day.

Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer. Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues (including breast tissue) that cover or line the internal organs, and in situ means "in its original place." DCIS is called "non-invasive" because it hasn’t spread beyond the milk duct into any normal surrounding breast tissue. DCIS isn’t life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on.

When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before. Most recurrences happen within the 5 to 10 years after initial diagnosis. The chances of a recurrence are under 30%.

Women who have breast-conserving surgery (lumpectomy) for DCIS without radiation therapy have about a 25% to 30% chance of having a recurrence at some point in the future. Including radiation therapy in the treatment plan after surgery drops the risk of recurrence to about 15%. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive (DCIS again) about half the time and invasive about half the time. (DCIS itself is NOT invasive.)

According to the American Cancer Society, about 60,000 cases of DCIS are diagnosed in the United States each year, accounting for about 1 out of every 5 new breast cancer cases.

There are two main reasons this number is so large and has been increasing over time:

People are living much longer lives. As we grow older, our risk of breast cancer increases.

More people are getting mammograms, and the quality of the mammograms has improved. With better screening, more cancers are being spotted early.

To the women following my blog - please get screened. Early detection is critical. Mammograms save lives!


Breast Cancer - Predicting Individual Risk

Came across this interesting article published in the Mayo Clinic newsletter:

Mayo Clinic researchers have moved closer to determining an individual woman's risk of developing breast cancer.

When a woman undergoes testing for the most common breast cancer genes, BRCA1 and BRCA2, it is usually because she wants to know if she will develop breast cancer. However, since mutations in these genes account for just a small fraction of all breast cancers, a negative test result doesn't mean she is in the clear. Likewise, testing positive doesn't presage a future tumor.

While it's true that certain specific genetic alterations could result in a 65 percent chance of developing breast cancer during one's lifetime, other alterations could be absolutely meaningless. With such a wide range of possible outcomes, the decision of whether or not to endure a prophylactic mastectomy can seem more like gambling than medicine.

But the innovative research of geneticist Fergus J. Couch, Ph.D., of Mayo Clinic in Rochester, Minn., who is combining family history data with laboratory techniques, is giving women the genetic information they need to make crucial personal health decisions.

A telling lineage

Dr. Couch, who cut his teeth as a postdoctoral fellow in the laboratory of geneticist Francis S. Collins, M.D., Ph.D., now director of the National Institutes of Health, is widely regarded as one of the international leaders in the genomics of breast cancer. In the early 1990s, Dr. Couch was involved in the initial characterization of the BRCA1 gene and helped discover the full-length BRCA2 gene. In 1997, he came to Mayo Clinic and continues to study these two genes, with renewed emphasis on the clinical implications of his findings.

Today, Dr. Couch leads a number of international collaborations to identify and catalogue the remaining genetic risk factors for breast cancer.

"You can imagine this information will be useful for developing risk models in the future," Dr. Couch explains, "because it is all about risk and individualization of risk. Rather than giving a woman some number that really just represents the average risk of disease, we want to be able to give her a risk that takes into account her specific environmental and genetic influences."

As Dr. Couch explains it, two women with the same high-risk mutation in a breast cancer gene — and thus the same 65 percent lifetime risk of breast cancer — could, in fact, have very different outcomes. Depending on how the other 20,000-odd genes in her genome might be acting in the background, one woman may develop breast cancer at an earlier age, and the other might not ever get it.

Eager to identify the genetic factors that modify the effects of the BRCA1 and BRCA2 genes, Dr. Couch teamed up with colleagues from around the world to form the Consortium of Investigators of Modifiers of BRCA1/2. This international team is using genomewide scans to identify genetic variants (single-gene polymorphisms) that could explain the great variability in risk between individuals.

So far, the consortium has tested DNA from 17,000 BRCA1 mutation carriers and 9,000 BRCA2 mutation carriers. For his part, Dr. Couch has already uncovered a number of modifiers that can take that average risk of 65 percent up to as high as 90 percent or down to as low as 30 percent.

"If you find people at super-high risk, they may very quickly decide to do prophylactic surgery, but if you find people at a lower risk, they may decide to delay or even forgo that mastectomy," Dr. Couch says. "So it has real clinical implications. Now we have to improve on this model so that it can be brought to the clinic to help women understand what their risk is and to make more-informed clinical decisions."

Seeking other causes

Known predisposition genes account for 45 percent of all familial breast cancer. The other 55 percent are unexplained.

Through another international consortium, Dr. Couch is looking for the causes of sporadic breast cancer, when the disease appears seemingly at random and with no apparent genetic cause. The endeavor, called the Breast Cancer Association Consortium, has studied 100,000 sporadic cases, pinpointing 60 different regions of the genome that increase the risk of breast cancer.

As part of this project, Dr. Couch and epidemiologist Celine M. Vachon, Ph.D., also of Mayo Clinic in Rochester, Minn., are investigating risk factors for a specific subset of the disease known as triple-negative breast cancer. Although it makes up only 12 percent of all cases, triple-negative breast cancer is the most aggressive form of the disease and is difficult to treat because the tumors don't contain estrogen, progesterone and HER2 receptors. By scanning the entire genome of 5,000 triple-negative breast cancer patients, the researchers have been able to identify nine new markers of the disease.

"The interesting thing about these particular markers is that we do not see some of them in the other forms of breast cancer, so they may be unique to triple negative breast cancers," Dr. Couch says. "Remember, we are looking at mutations present in every cell in the body, not just the tumor. So at the very basic blood level there are factors that specifically predispose you to triple-negative breast cancer."

Coming full circle

Dr. Couch's quest to uncover the causes of many different forms of breast cancer has led him from the laboratory to the clinic and back again. His work at the bench has demonstrated that BRCA2, a known DNA repair gene, has an important role in cell division.

This novel function may help to explain why BRCA2 mutant breast tumors have high levels of genome instability. For instance, many breast cancer tumors either lose or gain big chunks of the genome, including a section of chromosome 17. Dr. Couch began to wonder if having extra copies of the genes within that region might actually be driving cancer.

His laboratory genetically engineered a series of mice to contain more than the usual dose of these genes in the mammary gland. Two of these juiced-up genes caused breast cancer in the mutant mice. When researchers compared their results to tumors from breast cancer patients, they found that the activity levels of these same two genes were highest in patients with poor outcomes. Dr. Couch now believes they have found two novel breast cancer genes, and he is back in the lab trying to understand how they are involved in cancer metastasis and progression.

"It was interesting to take what we had found in human tumors, put it into mice, find the specific gene responsible, and then we take it back around and show that it does make sense with regard to the outcome and progression of patients," Dr. Couch says. "We just have to figure out how it all works, and how it fits into the overall picture of a woman's risk. That is all in the future."

Breaking breast cancer's code

For 1 out of every 10 women tested for breast cancer gene mutations, the findings are even more uncertain. Ten percent of test results reveal a change in the BRCA1 or BRCA2 genes, yet whether or not that genetic alteration will lead to cancer is not known.

In 2009, Dr. Couch launched another international consortium to determine which of these genetic changes, called variants of uncertain significance, are background genetic noise and which are harbingers of disease. This new consortium is combining family history studies with molecular biology to calculate the odds that a particular mutation is causing disease.

Today, this consortium includes 100 scientists and physician-researchers from 17 countries. It meets twice a year to share family information, functional data and new ideas for cataloguing the more than 2,000 variants of uncertain significance identified so far.

"What Dr. Couch has done is bring together people globally to accomplish things that no one institution could do on its own," says James N. Ingle, M.D., the Betty J. Foust, M.D., and Parents’ Professor at Mayo Clinic, and director of Mayo Clinic's Breast Cancer SPORE, which funds the new consortium. "One of the important parts of his work is the translation of this information so that no matter where in the world a woman is being seen, she knows whether her mutation is a bad result or a neutral result. The whole point of this is to bring advantage to the patient, who, in turn, could avoid these substantial prophylactic surgeries and also perhaps worry a little bit less about cancer."

BRCA1 and BRCA2 are by far the most common breast cancer-predisposing genes, yet they only account for 5 to 10 percent of all breast cancers, and less than half of all familial cases. So it is not surprising that Dr. Couch is also interested in discovering other breast cancer genes and risk factors.

He is going back to families whose members have breast cancer not explained by BRCA1 and BRCA2 mutations and sequencing their genes to look for genetic changes that track with disease. The research is in collaboration with the University of Delaware and City of Hope Comprehensive Cancer Center in California, but Dr. Couch is hoping to extend it across international lines and recently met with investigators from 20 research groups from around the world.



Breast Cancer Fund



The Breast Cancer Fund is working to shift public focus to prevention — to changing the odds so that far fewer people will ever have to hear the words “you have breast cancer.” Learn more about prevention here:

http://www.breastcancerfund.org/reduce-your-risk/tips

#safecosmetics #breastcancer #radiation #food


Charities

Two of my favorite charities:

www.standup2cancer.org

[This is a terrific one - and it's not just for breast cancer, but all cancers.] Their mission is to fund collaborative, translational cancer research to bring treatments from the bench to the bedside faster, and save lives now. Since Stand Up To Cancer was founded in May 2008, they have granted $161 Million Dollars to ten Dream Teams of scientists and researchers, one international translational research team and 26 high-risk, high-reward Innovative Research Grants. 100% of public funds go directly into research grants. A portion of the funds that are raised from major donations and third-party fundraising go towards administrative expenses and overhead.

Metavivor.org

From support groups to funding vital research, their programs sustain the power of hope. Passionately committed patients themselves, they rally public attention to the urgent needs of the metastatic breast cancer (MBC) community, help patients find strength through support and purpose, and make EVERY dollar count as they work with researchers to regain longevity with quality of life.

Pumpkin, Part II

Manoli and Denise went to Linvilla Orchards with Hannah. The pumpkin they brought back made me laugh so hard my stomach hurt!



Thanks kids for making me laugh. It's true - laughter is the best medicine.



One of my favorite Tim Burton movies is The Nightmare Before Christmas. Jack - the king of pumpkins!

Denise bought me a 'Jack' t-shirt a few years ago and it is one of my prized possessions.



'SOMETHINGS UP WITH JACK, SOMETHINGS UP WITH JACK ...'


Monday, October 6, 2014

Seroma

I learned a new word today: Seroma

After the most painful night since my surgery, I had to see Dr. Frazier today. He used two large needles to remove Seroma from under my armpit and under my incision. Seroma is blood and lymphatic liquid. I did not need an anesthetic because my skin is numb. My mother watched the procedure and cried. She kept saying, 'Mother Mary why didn't you give me my child's breast cancer.'

I kept telling my mom, 'I'm ok mom. It's ok.'

I feel much better - the pain is less intense and the swelling has gone down. Dr. Frazier gave me another prescription for Percocet and told me to take my pain meds.

Below I copied & pasted an article from John Hopkins that describes Seroma.

~~~~

Seroma Formation after Breast Cancer Surgery: What We Have Learned in the Last Two Decades

Formation of a seroma most frequently occurs after mastectomy and axillary surgery. Prolonged drainage is troublesome as it increases the risk for infection and can significantly delay adjuvant therapy. Seroma has been defined as serous fluid collection under the skin flaps or in the axillary dead space following mastectomy and/or axillary dissection. Because the true etiology of a seroma is unknown, a multifactorial-causation hypothesis has been accepted. Surgical factors include technique, extent of dissection and the surgical devices used for dissection. Obliteration of dead space with various flap fixation techniques, use of sclerosants, fibrin glue and sealants, octreotide, and pressure garments have been attempted with conflicting results and none have been consistent. Early movement of the shoulder during the postoperative period may increase the formation of seroma, although delayed physiotherapy decreases the formation of seroma. A detailed analysis of the use of drains showed that use of single or multiple drains, early or late removal, and drains with or without suction are not significantly different for the incidence of seroma. Although there is evidence for reduced seroma formation after early drain removal, very early removal within 24 hours seems to increase formation of seroma. No patient or tumor factors seem to affect seroma formation except body mass index and body weight. Consensus is lacking among studies/trials with different groups producing conflicting evidence. Besides a few established factors such as body mass index, the use of electrocautery for dissection, early drain removal, low vacuum drains, obliteration of dead space, and delayed shoulder physiotherapy, most of the hypothesized causes have not been demonstrated consistently. Thus, seroma remains a threat to both the patient and surgeon. Recurrent transcutaneous aspiration remains the only successful management.

Keywords: Breast neoplasms, Lymph node excision, Mastectomy, Seroma

INTRODUCTION

Breast cancer has remained the second leading cause of cancer death among women worldwide over the past three decades [1] and contributes significantly to cancer surgical load. Surgical treatment for breast cancer includes breast conservation therapy and mastectomy with or without axillary dissection depending on disease stage. Seroma formation is the most frequent postoperative complication seen after mastectomy and axillary surgery with an incidence of 3% to 85% [2]. It is so common that it is now believed to be a side effect of surgery rather than a complication. Associated morbidity in the form of prolonged drainage is not only troublesome to the patient but can also significantly impact treatment by delaying adjuvant therapy and increasing the risk for infection [2]. A reoperation may be necessary for cases of longstanding persistent seroma [3]. This review updates the various factors thought to contribute to seroma formation and the probable interventions that may be of help to reduce incidence.

PATHOPHYSIOLOGY

Seroma after breast surgery is defined as a serous fluid collection that develops under the skin flaps or in the axillary dead space following mastectomy and/or axillary dissection. The origin of seroma remains unclear but several risk factors and predictors are age, breast size, comorbid conditions, presence and number of malignant nodes in the axilla, previous surgical biopsy, and use of heparin or tamoxifen [4-6]. It has been hypothesized that seromas form as an exudate from an acute inflammatory reaction following surgical trauma [6] to increase serous fluid collection in response to increased fibrinolytic activity in serum and lymph [7]. Low fibrinogen levels in seromas compared with those in plasma during the postoperative period [8] support the hypothesis that seroma most likely originates from lymph [9]. Seroma formation is influenced by an array of surgical techniques and devices [10-13]; thus, leading to varying incidence of seroma in different studies.

FACTORS RELATED TO SURGERY

Techniques

Surgical treatment for breast cancer has undergone a paradigm shift from Halstead's radical mastectomy to breast conservation. It has been demonstrated that radical mastectomy increases seroma formation compared with that of simple mastectomy [14,15], but the association is inconclusive when radical mastectomy is compared with modified radical mastectomy (MRM) [14]. Conversely patients undergoing MRM have a significant increased incidence of seroma formation when compared to those who have breast conservation surgery [16]. Preservation or removal of the pectoral fascia has no effect on the incidence of seroma [17]. It has also been observed that immediate breast reconstruction following MRM decreases seroma formation when compared to a delayed procedure [18]. The number of removed lymph nodes probably does not influence seroma formation [19,20]. A randomized controlled trial by Purushotham et al. [21] demonstrated that sentinel lymph node biopsy is associated with significantly less seroma formation than that of conventional axillary dissection.

Surgical devices

Various electro-mechanical devices are used during surgery to reduce blood loss and operating time. These include electrocautery, laser scalpel, argon diathermy, ultrasonic scalpel, ultrasonic scissors, and vessel sealing systems. All of these devices have been investigated in an effort to reduce seroma formation. Randomized trials have shown that the use of electrocautery for dissecting flaps is significantly associated with increased seroma formation when compared to that of scalpel dissection [12,22]. However, no individual study has shown a significant effect on seroma formation with or without the use of a laser scalpel [23], argon diathermy [13], or an ultrasonic scalpel [24]. Ultrasonic scissors resulted in reduced seroma formation in a randomized controlled trial comparing level I and II axillary dissection using either ultrasound scissors or surgical scissors with ligation [25]. An Italian group compared the bipolar vessel sealing system with conventional surgical dissection and found no difference in the duration of the surgical procedure, total drainage fluid volume, drainage duration, or postoperative adverse events between the groups in a randomized trial [26]. Interestingly, a significant increase in seroma was observed in the vessel sealing system group. However other studies have reported improved results with use of a vessel sealing system. One of these was a prospective study [27], in which the results were compared with historical data, and decreased drainage duration and hospital stay were observed. Another retrospective study concluded that the drainage duration is significantly shorter with the use of a vessel sealing system but not the cost of treatment. The benefit in terms of fluid loss also remains to be demonstrated [28]. The differences in outcomes probably reflect differences in study methods; thus, further randomized trials with larger sample sizes are required.

OBLITERATION OF DEAD SPACE

Mechanical

Different techniques have been employed to obliterate the dead space (under flaps and the axilla) to reduce seroma formation. Halsted first advocated creating a short superior flap and suturing it with interrupted silk to the fascia below the first rib and skin grafting the remaining part of the defect [29]. In 1951, Orr [30] used tension sutures tied over rubber tubing bolsters to tack flaps to the chest wall. In 1953, Keyes et al. [31] used through and through sutures to attach the skin flaps to the chest wall. Besides these techniques, suturing of flaps with subcutaneous tissue [32], avoiding use of axillary drains following breast conservation therapy [33], and obliterating axillary dead space by muscle approximation [34,35] have all been tried for reducing seroma formation. Coveney et al. [36] compared suturing skin flaps to underlying muscle with conventional skin closure and observed a lower incidence of seroma formation in the flap suture group, although flap suturing did add to total operating time. A recent randomized study [37] compared a combination of skin flap suturing, ligation of lymphatics and obliteration of axillary dead space to conventional skin closure after mastectomy. As a result, the incidence of seroma formation decreased to 2% with the combination of techniques. Although effective, the authors stated that it was impossible to determine which of the three techniques, or any combination, actually produced the observed effect. Mechanical pressure has also been applied to obliterate dead space following surgery. The use of a pressure garment does not reduce postoperative drainage and has low tolerance and a higher complication rate [38,39].

Chemical

Fibrin glue [40], light activated fibrin sealant [41], and transdermal photo-polymerized adhesive [42] reduce seroma formation after mastectomy in animal models. Use of a fibrinolysis inhibitor was based on the hypothesis that fibrinolytic activity in serum and lymph might contribute to fluid accumulation. Sanders et al. [43] reported that fibrinogen and thrombin concentrations in the fibrin sealant are proportional to the reduction in seroma formation. However, no significant difference in the incidence of seroma formation occurred with the use of fibrin glue in human studies [44-46]. In contrast, Vaxman et al. [46] demonstrated in a randomized trial that use of fibrin glue actually increases seroma formation rate. The advantage of using fibrin glue comes from three other studies that demonstrated significantly reduced total seroma drainage [47], early drain removal [48], and reduced hospital stay [49]. Most of these studies had a limitation of a relatively small sample size. A reduction in postoperative drainage and hospital stay were observed following use of fibrin glue, but it did not affect delayed seroma formation [49]. However, the use of fibrin glue or peri-operative and postoperative administration of a fibrinolysis inhibitor does not reduce seroma formation [50].

Various sclerosants have also been used to prevent and manage seroma. A number of agents have been investigated in rat models, including marine mussel protein [51] and the Gram-positive anaerobe Corynebacterium parvum [52]. In humans, seromadesis has been reported with talc [53] and hypertonic saline [54]. Although successful, both of these reports were based on the experience of one patient. The most commonly reported sclerosant in the literature is tetracycline, and, similar to fibrin glue, some reports found it useful [55-57] whereas others did not [58,59]. Two prospective, randomized trials from the Mayo clinic evaluated the use of tetracycline. They first used tetracycline postoperatively, administering it into wound cavities via drains in patients who had undergone mastectomy [59]. This trial was aborted early due to severe pain experienced following the tetracycline administration with no associated benefit. A second trial administered tetracycline intra-operatively [58] and found no difference in postoperative pain between the groups but also found no difference in seroma formation. The non availability of tetracycline has led to the use of erythromycin as a sclerosant, which is commonly used in pleurodesis [60]. Ali-Khan et al. [61] showed that erythromycin was useful in one case of breast surgery and three cases of inguinal bloc dissection complicated by refractory seroma formation.
Somatostatin receptors have been discovered in the lymphatic tissue within and outside the gastrointestinal tract [62] and are thought to reduce lymph production when stimulated, although the precise mechanism of action responsible for this effect is not well understood. Octreotide, a long acting and 20 times more potent synthetic analogue of somatostatin has been used successfully to combat chylous ascites and lymphorrhoea following thoracic duct injury. Studies have demonstrated a benefit when administering octreotide following axillary lymph node dissection to reduce the to the duration and volume of lymphorrhoea [63]. However further trials are required to establish its true significance.


SHOULDER FUNCTION AND PHYSIOTHERAPY

Shoulder dysfunction is a common complication of mastectomy [64], and it is necessary to mobilize the shoulder early to prevent this complication. It was thought that early shoulder mobilization led to increased seroma formation and this hypothesis was supported by a systematic review of 12 randomized controlled trials (RCTs) of which six were included in a meta-analysis [65]. The study showed that a delayed shoulder exercise program reduces seroma formation (odds ratio, 0.4; 95% confidence interval, 0.2-0.5; p=0.00001) but no differences were found for drainage volume or hospital stay. Conversely, a number of RCTs have demonstrated no difference in seroma formation between early (within 1-2 days postoperatively) or late (by 5-7 days postoperatively) shoulder movement [20,66-68]. Temporary immobilization of the shoulder using a collar and cuff [20] or sling [66] has been attempted with an aim to reduce seroma formation but was not found to be beneficial. Thus, the present evidence does not support shoulder immobilization.

Another parallel issue is whether active shoulder mobilization through physiotherapy has any effect on seroma formation. A number of reports comparing delayed physiotherapy, even until removal of the drain showed less total wound drainage, shorter drainage period, and a shorter hospital stay without any difference in the functional range of movement in the longer term [68-70]. Rodier et al. [71] and van der Horst et al. [72] found no significant difference in seroma production to production following early or delayed physiotherapy. Thus delayed physiotherapy may reduce seroma formation at the expense of mild short-term shoulder dysfunction but without long term restriction of movement.

DRAINS

The use of drains has been a common practice to obliterate the dead space created after surgery [73,74]. The use of closed suction drainage in patients who underwent mastectomy accelerates wound healing and is also associated with a lower incidence of wound infection, necrosis, and breakdown [75,76]. A study by Bourke et al. [77] found no difference between using closed suction wound drainage and corrugated wound drainage in 51 patients who underwent simple mastectomy [78]. In a study by Whitfield and Rainsbury [79], no significant difference was observed between suction and closed siphon drainage on the formation of seroma. The choice of the number of drain tubes used has been studied. Two randomized trials reported that use of multiple drains does not confer any significant advantage on either the amount or duration of seroma drainage [80,81].
Studies comparing the intensity of negative drain suction have shown mixed results. In a study of 46 patients who underwent mastectomy, randomized between high vacuum drain and low vacuum drain, seroma drainage and postoperative hospital stay was longer in the low vacuum system group than that in the high vacuum system possibly because the high vacuum drain led to more efficient flap approximation to the chest wall [82]. In contrast, van Heurn and Brink [83] found that the mean volume evacuated was significantly lower from a low vacuum system, which lead to early drain removal in 76 patients who underwent axillary dissection with breast-conserving surgery. Bonnema et al. [84] compared high versus low vacuum drainage, in 141 patients undergoing modified radical mastectomy, lumpectomy with axillary dissection or axillary dissection alone. No significant difference was observed in the volume of axillary fluid produced, drainage duration or wound complication rates between the two groups. High vacuum drains had a higher incidence of vacuum loss but a lower incidence of leakage around the drain. Thus, no strong evidence is available to recommend high or low pressure suction to reduce seroma formation.

Discharge with drain in situ

Patients can be safely discharged with drains in situ with adequate patient education and coordination of inpatient and outpatient facilities, including telephone contacts [85,86]. Acceptance rates for early discharge with drains in situ vary between 24% and 41% [86,87]. Interestingly, patients who choose early discharge tend to be significantly younger, are living with another adult, and are more likely to have had breast-conserving surgery [88]. A number of studies have evaluated the effect of different days of postoperative discharges [86,88-92]. Early discharge from the hospital with the drain in situ does not appear to be associated with any untoward events [87,90,93]. Holcombe et al. [86] reported a lower seroma rate in the early discharge with drain in situ group (18%), compared to a standard treatment group (34%) and a reduction in median hospital stay of 5 days in a series of patients who underwent axillary dissection. However no significant decrease in seroma rates was observed with early discharge at a mean of 4.3 days [92]. Orr et al. [91] reported discharging 72 patients who had undergone total mastectomy and axillary dissection, segmental mastectomy and axillary dissection, or total mastectomy alone at a mean of 2.9 days. The seroma rate was as low as 11%. High seroma rates (45-67%) have been observed in patients who received mastectomy and were discharged the day following surgery [94,95].
Concerns expressed in the early discharge group of patients include personal care, bed posture, dressing themselves, fatigue, loneliness, pain, and worries about the wound and the arm [87]. Despite these factors, studies have shown that patient acceptance of early discharge with drains in situ remains good [87,91]. However, some reports have expressed mixed results and no compelling evidence points to a uniform reduction in seroma rate following early discharge with a drain in situ, although discharge within a day of surgery has been fraught with a higher rate of seroma formation.

Early drain removal

It is common practice to remove drains when drainage decreases to a minimal volume (20-50 mL) in the preceding 24 hours to minimize seroma formation [96]. It has been shown that 48 hours after surgery, as much as 74% of the total volume of seroma has been drained [97]. It has also been observed that drains may be safely removed after axillary dissection, if the total drainage during the first 3 days is less than 250 mL [98]. Somers et al. [19] studied 108 patients who underwent level one or two axillary node dissection, whose drains were removed on the first postoperative day regardless of drainage volume and the patients were discharged. No significant difference was observed with respect to drainage volume at the time of drain removal, subsequent mean number of aspirations, and time to resolution of seromas. Parikh et al. [99] randomized 100 patients who underwent mastectomy with axillary clearance to drain removal at either 3 or 6 days postoperatively. More seroma fluid was collected in the group whose drain was left in situ longer, but no difference in the volume, number, or duration of percutaneous aspirations was observed once the drain was removed. Inwang et al. [100] randomized 84 patients to drain removal on day 5 to drain removal when drainage was less than 20 mL over 2 consecutive days and found no significant difference in the mean number of aspirations required, wound complications or cosmesis. Yii et al. [101] compared drains removed at 48 hours to a "standard" removal group. No significant difference in drainage at 48 hours and no significant difference in seroma frequency were observed. Liu and McFadden [102] removed drains at 23 hours postoperatively in 50 patients who underwent axillary lymphadenectomy. Only a 2% seroma rate was observed, as 49 out of the 50 patients had no symptomatic seroma. Thus, there appears to be good evidence in favor of early drain removal.

No wound drainage

When drainage and no drainage were compared in patients who underwent lumpectomy and axillary dissection [19], short duration closed suction drainage appeared advantageous for decreasing the incidence and degree of seroma formation and did not seem to delay early hospital discharge. Cameron et al. [103] studied 40 patients who received axillary drainage and 20 who were allocated to no drain. The results showed a significantly higher rate of seroma formation in the undrained group (45% vs. 10%). Jeffrey et al. [104] reported safe axillary dissection without drainage after breast-conserving surgery, although this required frequent seroma aspiration. All seromas resolved clinically within 1 month or within 4 months on ultrasonographic examination. Siegel et al. [105] also reported that axillary dissections combined with breast-conserving surgery can be performed safely without axillary drainage. Zavotsky et al. [106] demonstrated that axillary node dissection can be managed with or without a drain. More aspirations in the no-drain group were required (50%) compared to that in the drain group (8.3%), but no difference was observed in the complication rate and the pain rating was significantly less in the no-drain group.

PATIENT FACTORS

Although a number of surgical technique-related factors have been described to play a role in seroma formation, most patient and tumor-related factors have been shown consistently to have no significant association with seroma formation. A number of studies have attempted to associate patient and tumour characteristics to postoperative seroma formation. Body weight [2,107] and body mass index [108] are associated with increased seroma formation, whereas no consistent association has been found between seroma formation and hormone receptor status [26,107], axillary nodal status, lymph node positivity [18,20,107] or disease stage and grade [18,26]. Similarly, no consistent association has been found between seroma formation and the presence of anemia, smoking, diabetes mellitus, or breast size [14]. Tumor size and location, histological type, site of the disease and specimen weight are not associated with increased seroma formation [26,109].

CONCLUSIONS

Seroma formation is a side effect of breast or axillary surgery rather than a complication but can delay patient recovery and cause unpleasant symptoms. Patient and tumor-related factors have no significant bearing on seroma formation except possibly body weight and body mass index, which seem to be directly proportional to seroma formation. Physical closure of the dead space appears to reduce seroma rate, but studies have failed to address the issues of cosmesis, and shoulder movement restrictions and these add to the operating time. Evidence for the use of fibrin glue remains controversial. Thrombin spray, sclerotherapy and mechanical pressure do not reduce seroma drainage. Shoulder immobilization is of no advantage to the patient, but it appears that delaying shoulder physiotherapy reduces drainage. Drains should be used, but the number of drain tubes or a low pressure system does not decrease the formation of seroma. However, low vacuum drains in the axilla result in less seroma formation, earlier drain removal and earlier discharge. High pressure vacuum drains in the axilla may promote increased drainage due to flap irregularity and poor flap adherence. High pressure vacuum drains appear safe and acceptable to discharge many patients early with drains in situ, if adequate patient counseling and nursing support are provided. Seroma formation can be safely considered on an outpatient basis by multiple percutaneous aspirations.

Underarm Pain

The pain under my armpit, which I have been told is normal after surgery, is intense. Sarah told me it could last for a long period of time.

I'm used to postoperative pain, been there - done that, with my 6 arm surgeries, but this pain is almost unbearable. Part of the discomfort is from the drains that were there. In addition to constant pain, I have numbness and burning sensations. It's very numb and feels very heavy, which Sarah told me is very normal.

The only time I should be concerned is if I have a fever, which I don't.

I never thought about my armpit before my surgery, but now, all of a sudden my armpit demands a lot of attention. In addition to the pain, I have swelling. I have numbness on the surface and soreness underneath. And with all the movement of my arm back and forth in that area, the whole area gets aggravated.

How do I control my underarm pain?

Percocet and ice. I haven't taken any percocet in two days because I don't want to rely on painkillers. If you can't feel any pain how will you know if something is wrong? This pain is nothing that I have ever experienced before. It's 2:15 am Monday morning. I can't sleep. Tomorrow I will call Dr. Frazier. I'm supposed to get rest so my body can heal but it is difficult with the constant pain.

Is it any wonder why cancer patients become addicted to opiates like morphine and Percocet?

I am doing my exercises everyday. My occupational therapist told me to do my exercises 3 to 4 times a day and to push myself as far as I can without feeling any pain. My range of motion is getting better and I can comb my hair, brush my teeth, take showers without help from my mom - normal tasks that most people take for granted.

Now I know why the nurse gave me 5 cotton ice bags when she gave me my discharge instructions. I wore 2 bags out already - on my third one. The ice helps with the discomfort and swelling and in turn alleviates some of the pain as a result of my sentinel lymph node dissection. The small pillow Sarah gave me that I position under my arm also helps some with the discomfort.

Pain. My 'new normal' ...

Sunday, October 5, 2014

the 'Grace of our Humanity' (what?!)



Get a load of the project by photographer Charise Isis called Grace. Isis, inspired by Hellenic sculpture, has assembled a collection of photographs of women who have had mastectomies as an 'exploration into the grace of their humanity.'



"It is a project that speaks about the strength and beauty that women who have survived Breast Cancer possess ... In photographing the project, I loosely use Hellenic sculpture as a visual reference for the portraits, taking inspiration from such artifacts as the 'Venus De Milo' and 'Nike of Samathrace'. These dismembered artifacts have survived the trauma of history and are still valued as objects of beauty within our culture."

The grace of our humanity, still valued as objects of beauty, blah, blah, blah ...

Yawn.

People start taking photographs of women with mastectomy scars and suddenly it’s pushing the aesthetic envelope. It begs the audience to empathize and then hold these women in high esteem because they have a disease, have gone through treatment, and survived. It must be noted that women and men with breast cancer are no braver, stronger, or aesthetically pleasing than anyone else who goes through the experience of cancer. Then why the imagery?

Women – particularly their breasts – have been objectified for centuries. Now we witness the objectification of mastectomy scars. Indeed, Isis emphasized that sculptures of antiquity, despite their amputations and scars, survived and are 'valued as objects of beauty within our culture.' Is the corollary, then, to value women as 'objects of beauty' in society? Do mastectomy and further surgery scars become 'objects' of beauty and bravery in breast cancer culture?

This project also perpetuates the iconic mythology of breast cancer – that to conquer breast cancer one must be strong and brave. It is the responsibility of the woman to defeat her disease and become a survivor. If she doesn’t survive? Well, she didn’t try hard enough.

Of course, in Grace they’ve all had cancer. We should not be surprised that women living with metastatic disease are absent from yet another pithy piece on breast cancer survivors. The ugly scars hold no interest if they are on a woman who has metastatic disease. Breast cancer isn’t about death. It is about pink ribbons, endurance, and survivorship.

The images try very hard, but they seem forced and largely uninspired. And although some may find inspiration in its images, my view is that as a body of work it objectifies the surgery, the scars, the physical detritus of breast cancer. The project has been traveling the United States for the past two years 'showcasing the brave subjects who bared their bodies for the camera, in the name of survivor solidarity.'

Bullshit.


Anaïs Nin

One of my favorite authors, Anaïs Nin, is keeping me company tonight. I have read her diaries - every volume - numerous times.

The last time I quoted her was when my cousin Tommy passed away. I got up, took the microphone from the priest, and recited a poem of hers at Tommy's luncheon.

"Love never dies a natural death.
It dies because we don't know how
to replenish its source. It dies of
blindness and errors and betrayals.
It dies of illness and wounds;
it dies of weariness, of witherings,
of tarnishings. ~ Anaïs Nin"

God.

What God would allow someone like my cousin Stanthoula to suffer for 21 years with a terminal illness? What God allows wars? What God allows hunger and pain? What God allows hate?

I question everything. I don't buy the old adage, the bullshit line religion feeds people, 'believe and don't question.'

Question everything.


Death is Everywhere

Death is everywhere,
There are flies on our windshields
Reminding us we could be torn apart.
Seems so unfair, I want to cry ...

Irene 10/5/14

Saturday, October 4, 2014

RIP cousin Stanthoula



My cousin Stanthoula passed away. RIP cousin. She suffered for 21 years with Multiple Sclerosis.

I called her brother, my cousin Nick, and we both kept crying. I'm going to get myself ready and will go see him.

"The sea of death carries away with each person we have loved or admired a little fragment of our soul's island. ~ Anais Nin"

To live on in the hearts of others is to never die.

See you on the other side cousin ...

Friday, October 3, 2014

Janice - same cancer, same fears

Janice called me up today. It was great talking to her. We have the same type of breast cancer (estrogen fed), the same hopes and fears.

Janice had her drains removed on Monday as well. On Wednesday, she noticed leaking. She went and saw Dr. Frazier today. It's normal to have some leaking but they will monitor her closely. She is at home now applying hot compresses.

Janice is also waiting for her tumor's profile from Oncotype. When she had a lumpectomy 10 years ago she had radiation and then was prescribed Tomaxifen. The Tomaxifen wreaked havoc on her digestive tract and made her nauseous. After a year, they switched her to Arimidex. She tolerated Arimidix well - the side effects were not that bad.

Sarah, my nurse navigator, told me I will probably have to take Arimidex.

We both are hoping that we won't have to have any chemotherapy. We dread the side effects: nausea, vomiting, head aches, loss of hair, loss of appetite, etc. I told Janice, if we do, we will cross that bridge as well. We have already been through enough.

We will get together next week one day for breakfast and then a walk. I look forward to seeing Janice. She is my 'battle buddy' in our 'war' against cancer.

I can relate to how she feels and she can relate to my hopes and fears.

Flowers

I got three orchids this week. I put them in the tower next to my other babies.

I must have flowers, always, and always. ~
Claude Monet




Thank you Betty!



Thank you Roula, Magda & Mema!



Thank you Anna-Maria!


Sleep Problems

Having a hard time sleeping. I am lucky if I fall asleep and if I do, it doesn't last for long. So grateful my cat Gypsy is next to me. It's pretty amazing how animals can sense when you are not well. She would always curl up next to me on my right side - always. Ever since my surgery, she sleeps on my left side.

Last Friday both Gypsy and I had a rough night. I still had my drains in and I fell asleep on my back. I was in considerable pain that night. I had a nightmare - someone was chasing me and I couldn't get away. I was screaming. Gypsy got scared and ran out of my room. My mom got up and ran to my rescue. When I woke up I started to cry and couldn't stop. My mom kept rubbing my forehead and telling me I was going to be okay.

When my mom finally went back to her room Gypsy started to wail in the hallway. My mom got back up and managed to get Gypsy back in my room.

I feel so sorry for my mom. She is tired. She worries a lot about me. Sometimes I'll be laying in bed resting and my mom will come in to check on me. I can hear her coming so I close my eyes and pretend that I am sleeping.

My mother has the strength of a thousand wild horses.

A week has gone by and I'm feeling much better. I have gone through an entire day (yesterday) without any pain meds.

I couldn't sleep last night. I heard my dad get up at 5:30. He fed Gypsy and came to check on me. I pretended to be asleep. I heard him go back and tell my mom, 'she's okay, she's sleeping.'



My mom comforting Gypsy.


Ying



"Until one has loved an animal a part of one's soul remains unawakened. ~ Anatole France"

Sunflower seeds for Ying.

Thursday, October 2, 2014

Arimidex



Sarah mentioned Arimidex.

Arimidex ® is the trade name for the generic drug anastrozole. In some cases, health care professionals may use the trade name Arimidex ® when referring to the generic drug name anastrozole.

Drug Type: Arimidex is a hormone therapy. Arimidex fights cancer as an "aromatase inhibitor." (For more detail see "How Arimidex Works" below).

What Arimidex Is Used For:

Arimidex is used to treat breast cancer in postmenopausal women.

Note: If a drug has been approved for one use, physicians sometimes elect to use this same drug for other problems if they believe it might be helpful.

How Arimidex Is Given:

Arimidex is a pill, taken by mouth.
You should take Arimidex at about the same time each day. You may take Arimidex with or without food. If you miss a dose, do not take a double dose the next day.

You should not stop taking Arimidex without discussing with your physician.

The amount of Arimidex that you will receive depends on many factors, including your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and how long you will be taking Arimidex.

Side Effects Of Arimidex:

Important things to remember about the side effects of Arimidex:

Most people do not experience all of the side effects listed.

Side effects are often predictable in terms of their onset and duration.

Side effects are almost always reversible and will go away after treatment is complete.

There are many options to help minimize or prevent side effects.

There is no relationship between the presence or severity of side effects and the effectiveness of the medication.

The following side effects are common (occurring in greater than 30%) for patients taking Arimidex:

Hot Flashes
Muscle/Joint pain

The following side effects are less common (occurring in 10-29%) for patients taking Arimidex:

Nausea (mild)
Decreased energy
Mood disturbances

Not all side effects are listed above, some that are rare (occurring in less than 10% of patients) are not listed here. However, you should always inform your health care provider if you experience any unusual symptoms.

When To Contact Your Doctor or Health Care Professional:

The following symptoms require medical attention, but are not emergency situations. Contact your health care provider within 24 hours of noticing any of the following:
Vaginal bleeding (similar to a period)
Always inform your health care provider if you experience any unusual symptoms.

Arimidex Precautions:

Before starting Arimidex treatment, make sure you tell your doctor about any other medications you are taking (including over-the-counter drugs, vitamins, or herbal remedies).
Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (Arimidex may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus).

If you are experiencing hot flashes, wearing light clothing, staying in a cool environment, and putting cool cloths on your head may reduce symptoms. Consult you health care provider if these worsen, or become intolerable.

Acetaminophen or ibuprophen may help relieve discomfort from generalized aches and pains. However, be sure to talk with your doctor before taking it.

Arimidex causes little nausea. However, to reduce nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals.

Get plenty of rest.

Maintain good nutrition.

If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.

Monitoring and Testing While Taking Arimidex:

You will be monitored regularly by your doctor while you are taking Arimidex, but no special tests or blood work are required.

How Arimidex Works:

Hormones are chemical substances that are produced by glands in the body, which enter the bloodstream and cause effects in other tissues. The use of hormone therapy to treat cancer is based on the observation that receptors for specific hormones that are needed for cell growth are on the surface of some tumor cells. Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell. The different types of hormone therapies are categorized by their function and/or the type of hormone that is effected.

Arimidex is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.

Scars

They say pain is meant to be felt.

We are asked, "on a scale from 1 to 10 how would you rate your pain?"

Physically? Mentally?

The amputation of our breasts is difficult to deal with. Processing it, accepting it and pushing through takes time.

My body has been through so much since my mastectomy. I have a hard time sleeping. I can't sleep on my right side and wonder if I will ever be able to sleep on that side. My body is still recovering physically.

When will my emotional recovery begin? Sarah told me it has already begun. I am navigating my 'new normal' so I am recovering.

I walk around wearing the same t-shirts I wore before my surgery. I can't forget my scars - I feel them through my shirts. When my shirts rub up against the 'battle area' I can feel it.

I am trying to navigate my way down the 'cancer road' ... I am figuring out which turn to take down this road. Adjusting to my 'new normal' will take time.



Some more new words to add to my cancer glossary:

NED= No Evidence of Disease
Protocol = A detailed plan for treatment

Wednesday, October 1, 2014

Breast Cancer Awareness Month



Hope. Strength. Love. Cure.

My Journey has Just Begun

In many ways, my journey is just beginning.

I am a different person than the woman who was diagnosed with cancer, and it is okay. Sarah is helping me navigate my 'new normal' because it's a hard road to try to go down on my own.

I was asked recently, 'how is your mental state?'

I have had to look in the mirror for a week and I can honestly say I am comfortable with who I am now. I have a ghastly scar, but that doesn't frighten me. It tells the story of how I am fighting to survive. I'm more concerned with my overall health. Fatigue, insomnia and worries about the future.

Cured ... I noticed this term is never used by Dr. Frazier or any of the nurses. Why? Because a recurrence can happen at any time.

Sarah asked me if I was experiencing any late effects. What are late effects? Sleep problems, depression, fatigue and any other health problem that starts after diagnosis and treatment.

I had depression before and have been taking Effexor for over 10 years. Insomnia? I have always had problems when it comes to sleeping. Fatigue? Aren't we all tired ...

I am learning new words every day that relate to cancer. I jot them down in my leather journal. Nikki gave it to me at work to help me with all of my appointments.

My own personal cancer glossary.

To all of the women who are battling breast cancer, stay strong. You are not alone.